biostudies-literatureParikh MNational Cancer Institute (NCI)Pharmaceuticals Bayer1946-1951https://www.ebi.ac.uk/biostudies/studies/S-EPMC12580894biostudies-literatureUnknown5(11)<h4>Purpose</h4>The ataxia telangiectasia and Rad3-related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin.<h4>Patients and methods</h4>Patients with advanced solid tumors who had received <300 mg/m2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy.<h4>Results</h4>Fifteen patients were enrolled.Cancer research communicationsThe ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).PMC12580894R50CA211241P30CA047904P30CA093373UM1CA186717U24CA247643Ruel CTam KDanilov AVFrankel PLara PNTakebe NParikh MBedard PLHolleran JLBeumer JHGore SDNoonan AMNewman EMYang YUboha NVWisinski KBYin MMittra AfalseThe ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).<h4>Purpose</h4>The ataxia telangiectasia and Rad3-related kinase inhibitor elimusertib synergizes with cisplatin preclinically. We evaluated the clinical feasibility of combining elimusertib with cisplatin.<h4>Patients and methods</h4>Patients with advanced solid tumors who had received <300 mg/m2 of prior cisplatin, and for whom cisplatin-based treatment was deemed appropriate, were enrolled according to a standard 3 + 3 design, starting elimusertib at 20 mg orally twice daily on days 2 and 9, with cisplatin 60 mg/m2 intravenously on day 1 of a 21-day cycle. Primary objectives were the determination of the maximum tolerated dose and safety. Secondary objectives included the assessment of elimusertib pharmacokinetics and preliminary efficacy.<h4>Results</h4>Fifteen patients were enrolled.2025-01-01T00:00:00Z2025 Nov2026-06-05T10:45:18.557Z2026-05-16T03:08:28.965ZS-EPMC125808944110471710.1158/2767-9764.CRC-25-0305